drug
as of 2026-07-01LY03010 156 mg treatment group, deltoid
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Luye Pharma Group Ltd.
1 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
SchizophreniaPsychotropic DrugsMood DisordersPhysiological Effects of DrugsMental DisordersSchizophrenia Spectrum and Other Psychotic DisordersMental DisordersSchizophreniaMood DisordersPsychotic DisordersNeurotransmitter AgentsTranquilizing AgentsPsychotic DisordersAntipsychotic AgentsMolecular Mechanisms of Pharmacological ActionSchizophrenia Spectrum and Other Psychotic Disorders
Trials
1
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
NCT05321602Phase 1Completed
KOLs & investigators
1
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
indication
KOL
Rui Li, MD
personKOL score —